Congruence Therapeutics Inc. has synthesized new melanocortin MC4 receptor antagonists potentially useful for the treatment of obesity.

Shanghai Meiyue Biotech Development Co. Ltd. has disclosed new molecular glue degraders comprising an E3 ubiquitin-protein ligase binding agents coupled to proto-oncogene Vav (VAV1) acting as VAV1 degradation inducers reported to be useful for the treatment of cancer, autoimmune diseases, cardiovascular, renal, metabolic, inflammatory and neurological disorders.

Changchun Genescience Pharmaceuticals Co. Ltd. has prepared and tested new steroid compounds acting as estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) inhibitors that are potentially useful for the treatment of endometriosis.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has discovered new tricyclic compounds acting as cyclin-dependent kinase 12 (CDK12)/cyclin k inhibitors reported to be useful for the treatment of cancer.

Researchers from Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have identified new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors that are potentially useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and more.

Montclair State University and the University of Maryland have discovered new dual 3’,5’-cyclic-AMP and -GMP phosphodiesterase 11A4 (PDE11A4) inhibitors potentially useful for the treatment of cognitive disorders.

The University of Toronto has patented new histone deacetylase 6 (HDAC6) inhibitors designed for use in the treatment of cancer, inflammation, neurodegeneration, infections, renal, neuromuscular, respiratory disorders and cardiometabolic syndrome.

Biofront Ltd. has designed new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety as HPK1 degradation inducers. They are described as potentially useful for the treatment of cancer.

Tyligand Bioscience Ltd. has reported new dual-drug antibody-drug conjugates comprising monoclonal antibodies covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonist and a cytotoxic drug.

Nimbus Salacia Inc. has disclosed new serine/threonine-protein kinase SIK2 (QIK) inhibitors potentially useful for the treatment of autoimmune disease, cancer, diabetes, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis and skin hyperpigmentation, among others.